Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.
Dabur India Ltd, in an effort to ensure maximum use of its leading mosquito repellant Odomos, has unveiled the Dengue-Fighters initiative aimed at preventing school-going children across the country. The company along with Apollo Hospitals Group began its campaign in Bengaluru, which will then cover schools across Delhi, Uttar Pradesh, Maharashtra and Tamil Nadu.
A new study says that combining chemotherapy with a drug that blocks part of the immune system may prevent cancer. The study published in the journal Cancer Research.
A new medication to be launched by the end of this year by US Pharma major Eli Lilly, for diabetic patients in India. A regulatory approval for the upcoming product has already been received by the company. It is also gearing up to introduce another medication in oncology that could be launched by the end of 2016 or early 2017 which has been filed for approvals.
The research suggests that female and male brains may respond differently to certain drugs. The study was published in The Journal of Neuroscience.
Generic Pramipexole dihydrochloride extended-release tablets for treatment of Parkinson's disease has been launched by Dr Reddy's Laboratories in the US market.
A new study claims that workout could help reduce daytime sleep disorder among depressed individuals. The study is published in the journal Translational sychiatry.
[adsense:336x280:8701650588]
Hydrogen sulfide present in rotten eggs plays an important role in autoimmune disease. The study is published in the journal Immunity.
Limonene, a natural compound present in lemons and oranges can help in early-stage diagnosis of liver disease. The study was published in the journal EBioMedicine.
Roche announced that in the large pivotal Phase II study, BIRCH, the investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PDL1) met its primary endpoint and shrank tumours (objective response rate; ORR) in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease expressed PD-L1 (Programmed Death Ligand-1). The study showed the amount of PD-L1 expressed by a person’s cancer correlated with their response to the medicine. Adverse events were consistent with what has been previously observed for atezolizumab.
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
